Ganirelix

Ganirelix is a decapeptide and a potent, competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to control ovarian hyperstimulation syndrome (OHSS).

Mechanism of Action

Ganirelix works by blocking the action of gonadotropin-releasing hormone (GnRH) on the pituitary gland. GnRH stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the ovaries to produce eggs and release estrogen. By blocking this action, Ganirelix prevents premature ovulation that can result in the release of eggs that are not ready for fertilization.

Uses

Ganirelix is used in fertility treatment to prevent premature ovulation in women undergoing controlled ovarian hyperstimulation (COH), as part of an assisted reproductive technology (ART) program. It allows for the timing of the luteinizing hormone surge, and consequently, the timing of ovulation, providing optimal conditions for fertilization and implantation.

Side Effects

Common side effects of Ganirelix include abdominal pain, headache, vaginal bleeding, and nausea. In rare cases, it can cause Ovarian Hyperstimulation Syndrome (OHSS), a condition where the ovaries swell and cause abdominal pain.

Contraindications

Ganirelix is contraindicated in women who are pregnant, have hypersensitivity to Ganirelix or any of its components, or have severe renal impairment.

See Also

• Gonadotropin-releasing hormone antagonist
• Assisted reproductive technology
• Ovarian hyperstimulation syndrome